B-Raf inhibitor 1 is primarily used in cancer research and treatment, specifically targeting cancers driven by mutations in the B-Raf gene, such as melanoma, colorectal cancer, and thyroid cancer. It works by inhibiting the activity of the B-Raf protein, which is part of the MAPK/ERK signaling pathway that regulates cell growth and division. By blocking this pathway, the inhibitor helps to slow down or stop the proliferation of cancer cells. It is often studied in preclinical models to understand its efficacy and potential side effects before being tested in clinical trials. Additionally, it serves as a tool for researchers to explore the mechanisms of B-Raf mutations and develop more effective targeted therapies.